Skip to main content
SpringerLink
Log in

Sundry Molecules

  • Chapter
  • First Online:
Central Pain Syndrome

  • 852 Accesses

Abstract

Several other molecules have been tried for CP. NSAIDs are useless, but tried by the vast majority of patients. Botulinum, which has pleiotropic actions (substance P/CGRP and glutamate block), and may have unexpected central effects, is interesting, but its effects are modest at best. Cholinergics (e.g., donepezil) have not been adequately tested, but may play some role as add-on therapy. Misoprostol (200 μg tid) is effective for MS-related trigeminal neuralgia (e.g., [1]). For other agents, the body of evidence is too thin to make any conclusion.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Pfau G, Brinkers M, Treuheit T, Kretzschmar M, Sentürk M, Hachenberg T. Misoprostol as a therapeutic option for trigeminal neuralgia in patients with multiple sclerosis. Pain Med. 2012;13(10):1377–8.

    Article  PubMed  Google Scholar 

  2. Ferguson AR, Huie JR, Crown ED, Grau JW. Central nociceptive sensitization vs. spinal cord training: opposing forms of plasticity that dictate function after complete spinal cord injury. Front Physiol. 2012;3:396.

    PubMed  PubMed Central  Google Scholar 

  3. Hansebout RR, Blight AR, Fawcett S, Reddy K. 4-aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients. J Neurotrauma. 1993;10(1):1–18.

    Article  CAS  PubMed  Google Scholar 

  4. Potter PJ, Hayes KC, Segal JL, Hsieh JT, Brunnemann SR, Delaney GA, Tierney DS, Mason D. Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury. J Neurotrauma. 1998;15(10):837–49.

    Article  CAS  PubMed  Google Scholar 

  5. Han ZA, Song DH, Oh HM, Chung ME. Botulinum toxin type A for neuropathic pain in patients with spinal cord injury. Ann Neurol. 2016;79:569–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Hamamci N, Dursun E, Ural C, Cakci A. Calcitonin treatment in reflex sympathetic dystrophy: a preliminary study. Br J Clin Pract. 1996;50(7):373–5.

    CAS  PubMed  Google Scholar 

  7. Barros TE Jr, Araujo FF, Higino Lda P, Marcon RM, Cristante AF. The effect of monosialoganglyoside (gm-1) administration in spinal cord injury. Acta Ortop Bras. 2016;24(3):123–6.

    Article  PubMed  Google Scholar 

  8. Yang ML, Li JJ, So KF, Chen JY, Cheng WS, Wu J, Wang ZM, Gao F, Young W. Efficacy and safety of lithium carbonate treatment of chronic spinal cord injuries: a double-blind, randomized, placebo-controlled clinical trial. Spinal Cord. 2012;50(2):141–6.

    Article  CAS  PubMed  Google Scholar 

  9. Rascol O, Zesiewicz T, Chaudhuri KR, Asgharnejad M, Surmann E, Dohin E, Nilius S, Bauer L. A randomized controlled exploratory pilot study to evaluate the effect of rotigotine transdermal patch on Parkinson’s disease-associated chronic pain. J Clin Pharmacol. 2016;56(7):852–61.

    Article  CAS  PubMed  Google Scholar 

  10. Di Biagio F. Dolore centrale da lesione sopratalamica regredito con atophanyl. Riv Neurol. 1959;29:476–81.

    Google Scholar 

  11. Hellwig K, Lukas C, Brune N, Schimrigk S, Przuntek H, Müller T. Repeat intrathecal triamcinolone acetonide application reduces acute occurring painful dysesthesia in patients with relapsing remitting multiple sclerosis. ScientificWorldJournal. 2006;6:460–5.

    Article  CAS  PubMed  Google Scholar 

  12. Hans G, Van Maldeghem K, Robert D. Intravenous administration of adenosine (Adenocor) in the treatment of severe, therapy-resistant, central neuropathic pain. Eur J Pain. 2007;11(S1):S145. A326

    Article  Google Scholar 

  13. Humble SR. Calcitonin for acute neuropathic pain associated with spinal cord injury. Anaesth Intensive Care. 2011;39(4):682–6.

    CAS  PubMed  Google Scholar 

  14. Kopsky DJ, Amelink GJ, Keppel Hesselink JM. Intractable neuropathic pain in spinal intramedullary cavernoma treated successfully with a novel combination cream. Pain Med. 2012;13(5):729–30.

    Article  PubMed  Google Scholar 

  15. Pellicane AJ, Millis SR. Efficacy of methylprednisolone versus other pharmacologic interventions for the treatment of central post-stroke pain: a retrospective analysis. J Pain Res. 2013;6:557–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Han ZA, Song DH, Chung ME. Effect of subcutaneous injection of botulinum toxin A on spinal cord injury-associated neuropathic pain. Spinal Cord. 2014;52(Suppl 1):S5–6.

    Article  PubMed  Google Scholar 

  17. Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M, Miyake S, Aranami T, Yamamura T. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology. 2014;82(15):1302–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Ringelstein M, Ayzenberg I, Harmel J, Lauenstein AS, Lensch E, Stögbauer F, Hellwig K, Ellrichmann G, Stettner M, Chan A, Hartung HP, Kieseier B, Gold R, Aktas O, Kleiter I. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol. 2015;72(7):756–63.

    Article  PubMed  Google Scholar 

  19. Trbovich M, Yang H. Capsaicin 8% patch for central and peripheral neuropathic pain of persons with incomplete spinal cord injury: two case reports. Am J Phys Med Rehabil. 2015;94:e66–72.

    Article  PubMed  Google Scholar 

  20. Batlle L, Mattie R, Irwin R. A medication combination for the treatment of central poststroke pain via the adjuvant use of prednisone with gabapentin: a case report. PM R. 2016;8(3):278–81.

    Article  PubMed  Google Scholar 

  21. Camoes-Barbosa A, Neves AF. The analgesic effect of abobotulinum and incobotulinum toxins type A in central poststroke pain: two case reports. PM R. 2016;8(4):384–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. HEAVEN/GEMINI International Collaborative Group, Turin, Italy

    Sergio Canavero

  2. AOUCittà della Salute e della Scienza di Torino, Department of Neurosciences, Rita Levi Montalcini, Università di Torino, Turin, Italy

    Vincenzo Bonicalzi

Authors
  1. Sergio Canavero
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vincenzo Bonicalzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Canavero, S., Bonicalzi, V. (2018). Sundry Molecules. In: Central Pain Syndrome. Springer, Cham. https://doi.org/10.1007/978-3-319-56765-5_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56765-5_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56764-8

  • Online ISBN: 978-3-319-56765-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation